Publications by authors named "Rob Scott"

Claim this Profile
D
Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting.
Trevor A Lentz, Lesley H Curtis, Frank W Rockhold, David Martin, Tomas L G Andersson, Rob Scott

Ther Innov Regul Sci· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
Gerald F Watts, Dick C Chan, Ransi Somaratne, Scott M Wasserman, Rob Scott

Eur Heart J· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.
Dick C Chan, Gerald F Watts, Ransi Somaratne, Scott M Wasserman, Rob Scott

Arterioscler Thromb Vasc Biol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Authors' response: Extracorporeal cardiopulmonary resuscitation probably good, but adoption should not be too fast and furious!
Brian Burns, Cliff Reid, Rob Scott, Stephen Bernard, Lionel Lamhaut

Emerg Med J· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
Thomas J Povsic, Rob Scott, Kenneth W Mahaffey, Robert Blaustein, Jay M Edelberg, Scott D Solomon, Scott M Wasserman

Cardiovasc Drugs Ther· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
Nihar R Desai, Robert P Giugliano, Scott M Wasserman, John P Gibbs, Thomas Liu, Rob Scott

JAMA Cardiol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Building a multicenter telehealth network to advance chronic disease management.
Saif Khairat, Namal Wijesinghe, Julian Wolfson, Rob Scott, Ray Simkus

Stud Health Technol Inform· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
Gerald F Watts, Dick C Chan, Ricardo Dent, Ransi Somaratne, Scott M Wasserman, Rob Scott

Circulation· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.
Leslie Cho, Michael Rocco, David Colquhoun, David Sullivan, Robert S Rosenson, Rob Scott, Scott M Wasserman

Cardiovasc Drugs Ther· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.
Frederick J Raal, Robert P Giugliano, Marc S Sabatine, Michael J Koren, Dirk Blom, Scott M Wasserman, Rob Scott

J Lipid Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Steven E Nissen, Erik Stroes, Ricardo E Dent-Acosta, Robert S Rosenson, Sam J Lehman, Scott M Wasserman, Rob Scott

JAMA· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
Payal Kohli, Peter Ganz, Yifei Ma, Rebecca Scherzer, Sophia Hur, Scott Wasserman, Rob Scott

J Am Heart Assoc· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Steven E Nissen, Ricardo E Dent-Acosta, Robert S Rosenson, Erik Stroes, Naveed Sattar, Scott M Wasserman, Rob Scott

Clin Cardiol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Evolocumab on Vitamin E and Steroid Hormone Levels: Results From the 52-Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled DESCARTES Study.
Dirk J Blom, C Stephen Djedjos, Maria Laura Monsalvo, Ian Bridges, Scott M Wasserman, Rob Scott

Circ Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular drug development: is it dead or just hibernating?
Christopher B Fordyce, Matthew T Roe, Tariq Ahmad, Peter Libby, Jeffrey S Borer, Scott M Wasserman, Scott D Berkowitz, Rob Scott

J Am Coll Cardiol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Frederick J Raal, Evan A Stein, Robert Dufour, Traci Turner, Fernando Civeira, Russell Scott, Rob Scott, Scott M Wasserman

Lancet· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
Frederick J Raal, Narimon Honarpour, Dirk J Blom, G Kees Hovingh, Feng Xu, Rob Scott, Scott M Wasserman

Lancet· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
Brandon Ason, José W A van der Hoorn, Joyce Chan, Edward Lee, Elsbet J Pieterman, Rob Scott, Scott M Wasserman

J Lipid Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.
Evan A Stein, Robert P Giugliano, Michael J Koren, Frederick J Raal, Eli M Roth, Scott M Wasserman, Rob Scott

Eur Heart J· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
Michael J Koren, Pernille Lundqvist, Michael Bolognese, Joel M Neutel, Maria Laura Monsalvo, Rob Scott, Scott M Wasserman

J Am Coll Cardiol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
Erik Stroes, David Colquhoun, David Sullivan, Fernando Civeira, Robert S Rosenson, Rob Scott, Scott M Wasserman

J Am Coll Cardiol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
Dirk J Blom, Tomas Hala, Michael Bolognese, Michael J Lillestol, Phillip D Toth, Rob Scott, Scott M Wasserman

N Engl J Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Jennifer G Robinson, Bettina S Nedergaard, William J Rogers, Jonathan Fialkow, Joel M Neutel, Rob Scott, Scott M Wasserman

JAMA· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy.
Jennifer G Robinson, William J Rogers, Bettina S Nedergaard, Jonathan Fialkow, Joel M Neutel, Rob Scott, Scott M Wasserman

Clin Cardiol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.
Frederick J Raal, Robert P Giugliano, Marc S Sabatine, Michael J Koren, Gisle Langslet, Scott M Wasserman, Rob Scott

J Am Coll Cardiol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis